Equities

Cardio Diagnostics Holdings Inc

CDIO:NAQ

Cardio Diagnostics Holdings Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.6927
  • Today's Change0.006 / 0.83%
  • Shares traded100.18k
  • 1 Year change-53.51%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

  • Revenue in USD (TTM)33.00k
  • Net income in USD-11.51m
  • Incorporated2021
  • Employees7.00
  • Location
    Cardio Diagnostics Holdings Inc311 W. Superior Street, Suite 444CHICAGO 60645United StatesUSA
  • Phone+1 (302) 281-2147
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mannatech Inc127.23m-1.66m14.60m213.00--1.40--0.1147-0.899-0.89968.075.542.771.93561.74597,342.80-3.624.39-9.679.1678.0177.87-1.311.720.5584--0.138488.33-3.83-5.3350.13---20.38--
Flora Growth Corp74.78m-47.58m14.74m97.00--3.29--0.1971-6.53-7.779.200.34941.485.9923.05770,958.80-92.50---140.01--21.72---62.66--0.6481--0.4952--127.75---1.87------
Oncotelic Therapeutics Inc70.00k-7.79m14.83m22.00--1.25--211.83-0.0197-0.01970.00020.02960.0021--3.613,181.82-24.46-25.03-49.25-48.76-----11,536.00-1,692.93---0.46960.5341-------255.12------
Inhibitor Therapeutics Inc0.00-3.17m15.10m3.00--3.25-----0.0184-0.01840.000.02690.00----0.00-34.0527.48-34.4832.70------------0.000.00-----125.39------
Chemomab Therapeutics Ltd - ADR0.00-19.34m15.21m20.00---------26.80-26.800.00--0.00----0.00-72.94---92.90----------------------12.39------
Tonix Pharmaceuticals Holding Corp10.25m-98.59m15.56m103.00--0.111--1.52-5.54-5.540.29561.470.0652----99,514.56-62.71-59.46-70.20-65.9237.55---961.87-5,126.730.8666--0.0767------0.1874--320.57--
Trinity Biotech plc (ADR)56.71m-33.88m15.62m380.00------0.2754-4.42-2.817.41-14.960.6251.693.67149,229.00-37.34-20.30-47.55-29.5434.2139.92-59.75-29.861.03-1.961.36---9.10-10.1515.41---31.08--
Cardio Diagnostics Holdings Inc33.00k-11.51m15.71m7.00--4.93--476.19-0.8257-0.82570.00210.14040.0051----4,714.29-178.70---325.81-------34,872.12-----4.840.0715--1,696.84---79.72------
Allied Corp21.51k-9.00m16.03m--------745.29-0.0915-0.09150.0002-0.07110.00511.650.1441---214.39-------6,919.57---41,861.41--0.0333-31.86-----56.46--31.30------
Galecto Inc0.00-30.83m16.48m13.00--0.5854-----1.15-1.150.001.040.00----0.00-63.50-48.46-78.33-52.36------------0.00------37.77------
Pharmacyte Biotech Inc0.00-14.82m16.57m2.00--0.5323-----1.64-1.640.005.740.00----0.00-1.53-13.35-1.62-13.70------------0.00-------1.81------
Talis Biomedical Corp989.00k-57.21m16.76m99.00--0.2958--16.95-31.44-31.440.543431.110.0092--14.879,989.90-53.08-68.18-58.71-74.2297.27---5,784.73-1,615.96----0.00---55.65-2.2445.13---1.83--
Nascent Biotech Inc0.00-2.09m16.80m----550.02-----0.0147-0.01470.000.00020.00-------346.80-815.53-----------548.75----0.8045---100.00---495.46------
Data as of May 31 2024. Currency figures normalised to Cardio Diagnostics Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

7.46%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Apr 20241.07m4.94%
The Vanguard Group, Inc.as of 31 Mar 2024232.14k1.08%
Geode Capital Management LLCas of 31 Mar 2024152.29k0.71%
SSgA Funds Management, Inc.as of 31 Mar 202443.50k0.20%
PNC Bank, NA (Investment Management)as of 31 Mar 202440.50k0.19%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202426.30k0.12%
Two Sigma Securities LLCas of 31 Mar 202416.93k0.08%
UBS Securities LLCas of 31 Mar 202412.52k0.06%
Bank Vontobel AGas of 31 Mar 202412.00k0.06%
Caldwell Sutter Capital, Inc. (Investment Management)as of 31 Mar 20248.10k0.04%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.